

### LIST OF FIGURES

Figure No	Title	Page No.
2.1	Barriers to brain delivery	13
2.2	Efflux transporters at Blood Brain Barrier	15
2.3	Anatomy and physiology of human nose	20
2.4	Pathways of nose to brain drug delivery	23
2.5	Pathophysiology, cellular events and therapeutic interventions of ischemic stroke	61
2.6	Homeostatic mechanisms involved in obesity	63
3.1	UV spectrophotometric scan of nicergoline in acetonitrile	86
3.2	Regressed calibration curve of estimation of nicergoline in acetonitrile	86
3.3	UV spectrophotometric scan of nicergoline in methanol	89
3.4	Regressed calibration curve of estimation of nicergoline in methanol	89
3.5	UV spectrophotometric scan of sibutramine base in acetonitrile	92
3.6	Regressed calibration curve of sibutramine base in acetonitrile	92
3.7	UV spectrophotometric scan of sibutramine base in methanol	94
3.8	Regressed calibration curve of sibutramine base in methanol	95
3.9	UV spectrophotometric scan of hydergine in acetonitrile	97
3.10	Regressed calibration curve of estimation of hydergine in acetonitrile	98
3.11	UV spectrophotometric scan of hydergine in methanol	100
3.12	Regressed calibration curve of estimation of hydergine in methanol	101
3.13	Spectrofluorimetric curve for $\lambda$ emission for PE-mAb-Tfr	104
3.14	Regressed calibration curve for estimation of PE-mAb-Tfr in PBS pH7.4	104
4.1	Schematic representation of emulsion solvent evaporation process	115
4.2	Contour plot for particle size of NNp	130
4.3	Contour plot for percentage drug entrapment efficiency of NNp	131
4.4	Contour plot for particle size of HNp	132
4.5	Contour plot for percentage drug entrapment efficiency of HNp	133
4.6	Contour plot for particle size of SNp	134
4.7	Contour plot for percentage drug entrapment efficiency of SNp	135
4.8	<sup>1</sup> H-NMR of [A] NNp [B] PE-mAb-Tfr-NNp	139
4.9	Particle size distribution plot of nicergoline nanoparticles before and after antibody conjugation	140
4.10	Zeta potential plot of nicergoline nanoparticles before and after antibody conjugation	140
4.11	Particle size distribution plot of hydergine nanoparticles before and after antibody conjugation	140
4.12	Zeta potential plot of hydergine nanoparticles before and after antibody conjugation	141

4.13	Particle size distribution plot of sibutramine nanoparticles before and after antibody conjugation	141
4.14	Zeta potential plot of sibutramine nanoparticles before and after antibody conjugation	141
4.15	In-vitro diffusion study data for drug containing formulations	142
4.16	Morphology of [A] NNp [B] PE-mAb-Tfr-NNp using TEM	143
4.17	Morphology of [A] HNp [B] PE-mAb-Tfr-HNp using TEM	143
4.18	Morphology of [A] SNp [B] PE-mAb-Tfr-SNp using TEM	143
4.19	DSC thermograms of [A] PLGA [B] NG [C] NNp	144
4.20	DSC thermograms of [A] PLGA [B] HG [C] HNp	144
4.21	DSC thermograms of [A] PLGA [B] SBMH [C] SB [D] SNp	145
5.1	Phase diagram of NG and HG microemulsion system (Capmul MCM, Tween 80: Transcutol P, Distilled Water)	179
5.2	Phase diagram of SB microemulsion system (Capmul MCM, Tween 80: Ethanol, Distilled Water)	179
5.3	Contour plots for globule size of nicergoline microemulsions	182
5.4	Contour plots for drug loading of nicergoline microemulsions	183
5.5	Contour plots for globule size of hydergine microemulsions	183
5.6	Contour plots for drug loading of hydergine microemulsions	183
5.7	Contour plots for globule size of sibutramine microemulsions	184
5.8	Contour plots for drug loading of sibutramine microemulsions	184
5.9	Particle size distribution plot of nicergoline microemulsion and mucoadhesive microemulsion	186
5.10	Zeta potential plot of nicergoline microemulsion and mucoadhesive microemulsion	186
5.11	Particle size distribution plot of hydergine microemulsion and mucoadhesive microemulsion	187
5.12	Zeta potential plot of hydergine microemulsion and mucoadhesive microemulsion	187
5.13	Particle size distribution plot of sibutramine microemulsion and mucoadhesive microemulsion	188
5.14	Zeta potential plot of sibutramine microemulsion and mucoadhesive microemulsion	188
5.15	TEM images of A NME B HME C SME	189
5.16	Cumulative percentage drug released Vs time plot for drug containing microemulsions	190
5.17	Cumulative percentage drug diffused Vs time plot for drug containing microemulsions	191
5.18	Optical microscopy of drug containing microemulsions treated nasal mucosa for nasal toxicity study	191
6.1	Effect of variable molar concentration of DTPA on radiolabeled <sup>99m</sup> Tc complex of nicergoline formulations	213
6.2	Brain concentrations versus time (hr) plot for NG formulations	217
6.3	Brain concentrations versus time (hr) plot for HG formulations	218
6.4	Brain concentrations versus time (hr) plot for SB formulations	218

6.5	Blood concentrations versus time (hr) plot for NG formulations	219
6.6	Blood concentrations versus time (hr) plot for HG formulations	219
6.7	Blood concentrations versus time (hr) plot for SB formulations	220
6.8	Gamma scintigraphy images of Balb/C mice (A/P view) showing the presence of radioactivity in brain following administrations of <sup>99m</sup> Tc labeled NG formulations	223
7.1	TTC stained brain slices	239
7.2	Effect of NG on infarct volume	240
7.3	Effect of NG on brain oedema	240
7.4	Effect of NG on brain glutathione (GSH)	240